LIS-1 is under clinical development by Xenothera and currently in Phase II for Kidney Transplant Rejection. According to GlobalData, Phase II drugs for Kidney Transplant Rejection have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LIS-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LIS-1 (polyclonal antibodies) are under development for kidney transplantation, graft versus host disease and graft rejection following solid organ transplantation. The drug candidates are polyclonal antibodies developed based on Xenothera technology platform involving generation of hyperimmune polyclonal sera. It is administered through intravenous route.
Xenothera, is a xenotherapy platform with embedded technology that renovates immunological treatments. The company is headquartered in France.
For a complete picture of LIS-1’s drug-specific PTSR and LoA scores, buy the report here.